Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sacituzumab tirumotecan with or without bevacizumab versus standard maintenance in newly diagnosed HRD-negative advanced ovarian cancer
MOH_2026-01-22_015615Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Sacituzumab tirumotecan, Sacituzumab tirumotecan + bevacizumab and Standard care: bevacizumab or observation (3 arms). Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2026-01-22_015615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-22_015615.